60 likes | 88 Views
Get more details @ http://bit.ly/2oX0vzB <br>Genitourinary Drugs Market Size, Industry Analysis Report, Regional Outlook (U.S., Germany, UK, Italy, Russia, China, India, Japan, South Korea, Brazil, Mexico, Saudi Arabia, UAE, South Africa), Application Growth Potential, Competitive Market Growth & Forecast, 2016 – 2024
E N D
Genitourinary Drugs Market – Global Industry Analysis Report, Share, Growth, Price Trends and Forecast, 2016 – 2024: Global Market Insights Inc. Fuel Cell Market size worth $25.5bn by 2024 Low Power Wide Area Network
Regional Analysis of Genitourinary Drugs Market: • U.S. genitourinary drugs market size held a large share of the global genitourinary drugs in 2015 due to robust healthcare infrastructure, growing awareness, and technological advancements in the development of genitourinary drugs. • Canada genitourinary drugs market share is driving due to the burden of cancer disease in the country. As per the Canadian Cancer Statistics in 2015, about 196,900 people diagnosed with cancer. • Europe genitourinary drugs market will witness a significant growth over the forecast timeframe. It was estimated that over 78% of the new cancer medicines that were introduced between 2010 and 2014 are available within the greater EU. • APAC should witness a lucrative growth during the forecast period owing to the increasing R&D in China and India, high disposable income, and growing awareness in these emerging countries.
Application Analysis of Genitourinary Drugs Market: • Increasing prevalence of genitourinary disorders, rising disposable incomes, and constant improvements in healthcare infrastructure will drive genitourinary drugs market over the forecast timeframe. • Patients with diabetes are highly susceptible to suffer from urinary tract infections. Women are more disposed to this problem due to the short length of urethra that facilitates easier entry of microorganisms. • Prostate cancer contributed to over 25% revenue share in 2015. A wide range of therapeutics, such as radiopharmaceuticals, immunotherapy medication, and anti-neoplastic agents, available to treat prostate cancer will drive this segment’s growth. • Urinary Tract Infections (UTIs) affect more than 150 million people every year worldwide, resulting in direct healthcare expenses of over USD 6 billion.
Competitive Market Share of Genitourinary Drugs Market: • Some of the companies operating in this industry include Abbott Laboratories, Astellas, Bayer, Bristol-Myers Squibb, Eli Lilly, Pfizer, Genentech, GlaxoSmithKline, Merck, Hoffman-La Roche, Immunex, and Ionis Pharmaceuticals. • Companies are focusing on the implementation of strategies including mergers & acquisitions, new product development, and regional expansion. In October 2016, the U.S. FDA approved a supplemental Biologics License Application (sBLA) of Bristol-Myers Squibb, to enlarge the practice of Opdivo (nivolumab) to treat patients suffering from an advanced form of bladder cancer.
Browse Full Market Research Report On Genitourinary Drugs Market @ http://bit.ly/2nHAJiE Request for an in-depth table of contents for this report @ https://www.gminsights.com/request-toc/upcoming/1382
Stay In Touch Website: www.gminsights.com Social Media: